Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases and multi-drug resistant bacterial infections, announced it will release its third quarter 2024 financial results on Thursday, November 14, 2024, after the market close. The company will also provide a business update at that time. Notably, Spero Therapeutics will not host a conference call to discuss the results.
Spero Therapeutics (Nasdaq: SPRO), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento di malattie rare e infezioni batteriche multiresistenti, ha annunciato che pubblicherà i suoi risultati finanziari del terzo trimestre 2024 il giovedì 14 novembre 2024, dopo la chiusura del mercato. L'azienda fornirà anche un aggiornamento sulle attività in quel momento. È importante notare che Spero Therapeutics non terrà una conferenza telefonica per discutere i risultati.
Spero Therapeutics (Nasdaq: SPRO), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades raras e infecciones bacterianas multirresistentes, anunció que dará a conocer sus resultados financieros del tercer trimestre de 2024 el jueves 14 de noviembre de 2024, después del cierre del mercado. La empresa también proporcionará una actualización comercial en ese momento. Cabe destacar que Spero Therapeutics no llevará a cabo una conferencia telefónica para discutir los resultados.
Spero Therapeutics (Nasdaq: SPRO)는 희귀 질환 및 다제내성 세균 감염 치료를 전문으로 하는 임상 단계의 바이오 제약 회사로, 2024년 3분기 재무 결과를 2024년 11월 14일 목요일에 시장 마감 후 발표할 예정이라고 발표했습니다. 이 회사는 그때 사업 업데이트도 제공할 것입니다. 주목할 점은 Spero Therapeutics가 결과에 대해 논의하는 전화 회의를 개최하지 않을 것이라는 점입니다.
Spero Therapeutics (Nasdaq: SPRO), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements pour les maladies rares et les infections bactériennes multirésistantes, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 le jeudi 14 novembre 2024, après la clôture du marché. L'entreprise fournira également une mise à jour commerciale à ce moment-là. Il est à noter que Spero Therapeutics ne tiendra pas de conférence téléphonique pour discuter des résultats.
Spero Therapeutics (Nasdaq: SPRO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Behandlungen für seltene Krankheiten und multiresistente bakterielle Infektionen spezialisiert hat, gab bekannt, dass es am Donnerstag, den 14. November 2024, nach Marktende seine Finanzergebnisse für das 3. Quartal 2024 veröffentlichen wird. Das Unternehmen wird zu diesem Zeitpunkt auch ein Update zum Geschäft geben. Es ist erwähnenswert, dass Spero Therapeutics keine Telefonkonferenz zur Diskussion der Ergebnisse abhalten wird.
- None.
- None.
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2024 financial results and provide an update on its business on Thursday, November 14, after the market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information - www.sperotherapeutics.com
Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com
Media Inquiries:
media@sperotherapeutics.com
FAQ
When will Spero Therapeutics report its third quarter 2024 financial results?
Will Spero Therapeutics host a conference call for the third quarter 2024 financial results?
What is the stock symbol for Spero Therapeutics?
What type of company is Spero Therapeutics?
